Advanced

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.

Bolin, Kristian LU ; Wilson, Koo; Benhaddi, Hicham; Nigris, Enrico de; Marbaix, Sophie; Mork, Ann-Christin and Aubin, Henri-Jean (2009) In European Journal of Public Health 19(6). p.650-654
Abstract
BACKGROUND: The aim of this study was to evaluate and compare the cost-effectiveness of varenicline with nicotine replacement therapy (NRT) for smoking cessation in four European countries (Belgium, France, Sweden and the UK). METHODS: Markov simulations, using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, were performed. We simulated the incidence of four smoking-related morbidities: lung cancer, chronic obstructive pulmonary disease, coronary heart disease and stroke. The model computes quality-adjusted life-years gained and incremental cost-effectiveness ratios. Incremental cost-utility ratios were calculated, adopting a lifetime perspective. Efficacy data were obtained from a randomized open-label trial: Week 52... (More)
BACKGROUND: The aim of this study was to evaluate and compare the cost-effectiveness of varenicline with nicotine replacement therapy (NRT) for smoking cessation in four European countries (Belgium, France, Sweden and the UK). METHODS: Markov simulations, using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, were performed. We simulated the incidence of four smoking-related morbidities: lung cancer, chronic obstructive pulmonary disease, coronary heart disease and stroke. The model computes quality-adjusted life-years gained and incremental cost-effectiveness ratios. Incremental cost-utility ratios were calculated, adopting a lifetime perspective. Efficacy data were obtained from a randomized open-label trial: Week 52 continuous abstinence rates were 26.1% for varenicline and 20.3% for NRT. RESULTS: The analyses imply that for countries analysed, smoking cessation using varenicline versus NRT was associated with reduced smoking-related morbidity and mortality. The number of morbidities avoided, per 1000 smokers attempting to quit, ranged from 9.7 in Belgium to 6.5 in the UK. The number of quality-adjusted life-years gained, per 1000 smokers, was 23 (Belgium); 19.5 (France); 29.9 (Sweden); and 23.7 (UK). In all base-case simulations (except France), varenicline dominated (more effective and cost saving) NRT regarding costs per quality-adjusted life-year gained; for France the incremental cost-effectiveness ratio was 2803. CONCLUSION: This cost-effectiveness analysis demonstrated that since varenicline treatment was more effective, the result was increased healthcare cost savings in Belgium, Sweden and the UK. Our results suggest that funding varenicline as a smoking cessation aid is justifiable from a healthcare resource allocation perspective. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
nicotine replacement therapy, cost-effectiveness, smoking cessation, varenicline
in
European Journal of Public Health
volume
19
issue
6
pages
650 - 654
publisher
Oxford University Press
external identifiers
  • wos:000272179400022
  • pmid:19491286
  • scopus:71449103289
ISSN
1101-1262
DOI
10.1093/eurpub/ckp075
language
English
LU publication?
yes
id
16b2f74b-1db3-4008-a9bc-584e7c011d20 (old id 1434591)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19491286?dopt=Abstract
date added to LUP
2009-07-01 17:00:01
date last changed
2017-09-10 03:45:03
@article{16b2f74b-1db3-4008-a9bc-584e7c011d20,
  abstract     = {BACKGROUND: The aim of this study was to evaluate and compare the cost-effectiveness of varenicline with nicotine replacement therapy (NRT) for smoking cessation in four European countries (Belgium, France, Sweden and the UK). METHODS: Markov simulations, using the Benefits of Smoking Cessation on Outcomes (BENESCO) model, were performed. We simulated the incidence of four smoking-related morbidities: lung cancer, chronic obstructive pulmonary disease, coronary heart disease and stroke. The model computes quality-adjusted life-years gained and incremental cost-effectiveness ratios. Incremental cost-utility ratios were calculated, adopting a lifetime perspective. Efficacy data were obtained from a randomized open-label trial: Week 52 continuous abstinence rates were 26.1% for varenicline and 20.3% for NRT. RESULTS: The analyses imply that for countries analysed, smoking cessation using varenicline versus NRT was associated with reduced smoking-related morbidity and mortality. The number of morbidities avoided, per 1000 smokers attempting to quit, ranged from 9.7 in Belgium to 6.5 in the UK. The number of quality-adjusted life-years gained, per 1000 smokers, was 23 (Belgium); 19.5 (France); 29.9 (Sweden); and 23.7 (UK). In all base-case simulations (except France), varenicline dominated (more effective and cost saving) NRT regarding costs per quality-adjusted life-year gained; for France the incremental cost-effectiveness ratio was 2803. CONCLUSION: This cost-effectiveness analysis demonstrated that since varenicline treatment was more effective, the result was increased healthcare cost savings in Belgium, Sweden and the UK. Our results suggest that funding varenicline as a smoking cessation aid is justifiable from a healthcare resource allocation perspective.},
  author       = {Bolin, Kristian and Wilson, Koo and Benhaddi, Hicham and Nigris, Enrico de and Marbaix, Sophie and Mork, Ann-Christin and Aubin, Henri-Jean},
  issn         = {1101-1262},
  keyword      = {nicotine replacement therapy,cost-effectiveness,smoking cessation,varenicline},
  language     = {eng},
  number       = {6},
  pages        = {650--654},
  publisher    = {Oxford University Press},
  series       = {European Journal of Public Health},
  title        = {Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.},
  url          = {http://dx.doi.org/10.1093/eurpub/ckp075},
  volume       = {19},
  year         = {2009},
}